Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database
Study Details
Study Description
Brief Summary
The goal of this observational study is to compare severity and mortality rates of acute cerebral infarction(requiring thrombolysis or endovascular recanalization) depending on the type of oral antidiabetic drug taken before the onset of cerebral infarction.
Researchers will compare the group that used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction and the group that did not use them to see the effect of DPP-4 inhibitors in reducing severity of cerebral infarction.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This is a retrospective study to see the effects of reducing the severity of cerebral infarction(requiring thrombolysis or endovascular recanalization) of DPP-4 inhibitors by comparing the survival rate after acute cerebral infarction hospitalization, discharge rate to home, and medical cost.
-
Severity of cerebral infarction and poor prognosis is mainly associated with hyperglycemia caused by diabetes, which increases the Infarction volume and hemorrhagic trasformation.
-
However, the effect of loergin blood glucose on reducing the Infarction volume and improving prognosis of cerebral infarction has not been proven.
-
Preclinical studies have demonstrated a anti-stroke effect that reduces the Infarction volume using certain anti-diabetic drugs.
-
Therefore, there is a possibility that certain anti-diabetic drugs may reduce the severity of cerebral infarction as a class effect in addition to the effect of blood sugar control.
-
This is particularly likely to exist in the DPP-4 inhibitor family identified through preclinical studies.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| DPP4i used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization) Combination therpay is acceptable. |
Drug: Dipeptidyl peptidase-4 inhibitor
The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
Other Names:
|
| except DPP4i patients that did not use DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization) |
Outcome Measures
Primary Outcome Measures
- 1-year survival rate [Check the data one year after the onset of stroke.]
The survival rates of the DPP-4 inhibitor group and the non-use group are compared 1 year after the onset of severe stroke.
- 90-day survival rate [Check the data 90-day after the onset of stroke.]
The survival rates of the DPP-4 inhibitor group and the non-use group are compared 90-day after the onset of severe stroke.
- re-hospitalization [1 year after discharge the stroke treatment.]
The re-hospitalization rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke.
- frequency of cerebral hemorrhage [Hospitalization period and 1 year after discharge the stroke treatment.]
The frequency of cerebral hemorrhage rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke.
- Rate of Intensive care unit treatment [Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.]
The Intensive care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared.
- Duration of Intensive care unit [Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.]
The duration of Intensive care unit of the DPP-4 inhibitor group and the non-use group are compared.
- Rate of Stroke care unit treatment [Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.]
The Stroke care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared.
- Duration of Stroke care unit [Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.]
The duration of Stroke care unit of the DPP-4 inhibitor group and the non-use group are compared.
- tracheal intubation period [Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.]
The tracheal intubation period of the DPP-4 inhibitor group and the non-use group are compared.
- total hospitalization days [Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.]
The total hospitalization days of the DPP-4 inhibitor group and the non-use group are compared.
- medical expenses incurred at the time of hospitalization [Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.]
The medical expenses incurred at the time of hospitalization of the DPP-4 inhibitor group and the non-use group are compared.
Secondary Outcome Measures
- Home discharge rate [At the end of discharge from stroke treatment.]
The Home discharge rate of the DPP-4 inhibitor group and the non-use group are compared.
- medical expenses after discharge from hospital [1 year after discharge the stroke treatment.]
The medical expenses after discharge from hospital of the DPP-4 inhibitor group and the non-use group are compared.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with acute cerebral infarction who underwent thrombolysis or endovascular recanalization in Korea between 2014 and 2021
-
Those who have been previously diagnosed with diabetes and are taking oral anti-diabetic drugs
-
Adult (over 19 years of age)
-
The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
Exclusion Criteria:
- Patients taking insulin to control diabetes
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Ajou University School of Medicine
- Dong-A ST Co., Ltd.
Investigators
- Principal Investigator: DukYong Yoon, MD., PhD., Department of Biomedical Systems Informatics,Yonsei University College of Medicine,Yongin,SouthKorea
- Principal Investigator: Seong-Joon Lee, MD., PhD., Department of Neurology, Ajou University School of Medicine, Suwon, South Korea
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AJOUIRB-EX-2023-089